Epigral Limited Schedules Q2 FY27 Results Call for November 2

Epigral Limited has scheduled a conference call at 5:00 pm IST on November 2, 2026, to discuss its Q2 FY27 results with investors and analysts. The call follows a board meeting set for the same day to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.

When will Epigral Limited discuss its Q2 FY27 results?

Epigral Limited will hold its Q2 FY27 earnings conference call on Monday, November 2, 2026, at 5:00 pm IST. The company disclosed the event to the National Stock Exchange of India and BSE under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations.

The company has also said its board of directors will meet on November 2 to consider and approve unaudited standalone and consolidated financial results for the second quarter and first half of FY27. The reporting period covers July 1, 2026 to September 30, 2026.

The exchange intimation dated October 28 records the planned call as an analyst and investor meet. A separate intimation stated that the board would consider the September-quarter and half-year financial statements on the same date. The disclosures establish the date of the corporate event, although the financial results themselves were not included in the information provided.

Who will participate in the Epigral results call?

Epigral said the call will include Chairman and Managing Director Maulik Patel, Executive Director Kaushal Soparkar, Chief Financial Officer Rakesh Agrawal and investor relations head Milind Kotecha. Emkay Global Financial Services is supporting the conference call arrangement.

The company has invited investors and analysts to participate through dial-in facilities arranged for the call. Management commentary on quarterly operating conditions, product demand, prices, capacity utilisation and capital expenditure is generally a key part of these interactions, but no such commentary has been disclosed ahead of the event.

The company has previously made the audio recording of its Q1 FY27 results call available on its website. Its investor resources also include quarterly presentations, annual reports and earnings-related documents, providing shareholders with access to prior disclosures.

What is the financial context before Epigral's Q2 FY27 update?

Epigral reported revenue of Rs 705.00 crore and net profit of Rs 100.00 crore in Q1 FY27, according to the information available. The company also reported 15% year-on-year revenue growth and 25% year-on-year growth in profit after tax for that quarter.

For comparison, the September 2025 quarter, or Q2 FY26, had revenue of Rs 587.00 crore and profit of Rs 51.00 crore. Another reported Q2 FY26 disclosure placed revenue at Rs 589.10 crore, EBITDA at Rs 132.00 crore and net profit at Rs 51.52 crore. The differing revenue and profit figures in the available material should be read in the context of the underlying reported documents and whether they refer to standalone or consolidated results.

Q2 FY26 was affected by lower price realisations in products including CPVC, hydrogen peroxide and caustic soda. Reported sales volumes rose 2%, while revenue declined as pricing weakened. An extended monsoon and plant maintenance were also cited as factors affecting performance during that period.

Why does the Q2 FY27 call matter to investors?

The November 2 call gives investors an opportunity to hear management explain the Q2 FY27 financial results after the board considers them. The discussion will be relevant for assessing the company against the year-ago September-quarter base and the Q1 FY27 performance disclosed earlier.

Epigral operates in chlor-alkali and specialty chemicals, with products including caustic soda, chloromethanes and related derivatives. Its end markets include alumina, textiles, agrochemicals, pharmaceuticals and other industrial applications. Consequently, volume trends and realisations across these product lines are important factors in interpreting quarterly revenue and profitability.

The company had previously indicated progress on capital expenditure initiatives, including CPVC capacity expansion and a wind-solar hybrid power project. The supplied disclosures do not provide an updated implementation schedule, cost figure or operating contribution for these projects. Investors will therefore look for any formal update made alongside the Q2 FY27 results.

What disclosures should investors watch on November 2?

Investors should watch for the unaudited revenue, EBITDA, margin and profit figures for the September 2026 quarter, along with the corresponding half-year numbers. The exchange filing is also expected to contain notes to the accounts and may clarify the basis of comparison with earlier periods.

Management's comments on sales volumes, product pricing, plant operations and ongoing projects will also be relevant. However, the pre-result notice only confirms the board meeting and conference call. It does not provide a revenue estimate, earnings forecast, guidance revision or confirmed operational update for Q2 FY27.

Conclusion

Epigral Limited has formally scheduled its Q2 FY27 results discussion for November 2 at 5:00 pm IST, after the board considers unaudited standalone and consolidated results for the quarter and half year ended September 30. The event is important because it will provide the first official financial update for the September quarter and management's explanation of the reported numbers.

The main points to watch are the Q2 FY27 filing, comparison with the Q2 FY26 revenue base of about Rs 587.00 crore, and any official comments on pricing, volumes and capital expenditure projects. The company has not disclosed the Q2 FY27 financial figures in the announcement ahead of the scheduled board meeting and call.